Drug Profile
Dapatifagene navolactibac - Precigen Inc/Oragenics
Alternative Names: AG 013; Lactococcus lactis expressing human trefoil factor 1; Lactococcus lactis secreting human trefoil factor 1Latest Information Update: 01 Sep 2020
Price :
$50
*
At a glance
- Originator ActoGeniX
- Developer Oragenics Inc; Precigen Inc
- Class Bacteria; Peptides
- Mechanism of Action Mucoprotein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stomatitis
Most Recent Events
- 10 Jul 2020 Oragenics and Precigen terminates its licence agreement for dapatifagene navolactibac
- 10 Jul 2020 Discontinued - Phase-II for Stomatitis in USA, United Kingdom, Belgium, Germany (Topical) due to overall lack of efficacy and strategic product portfolio considerations
- 10 Jul 2020 Oragenics terminates a phase II trial for Stomatitis in USA, United Kingdom, Belgium, Germany (Topical) due to overall lack of efficacy and strategic product portfolio considerations